Patented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus
Re-Issuance of U.S. Patent No. RE 47,471 further bolsters Mucosis’ intellectual property portfolio
Groningen / Odijk, The Netherlands, July 2, 2019 – The trustee of biotech company Mucosis B.V., Mr. Holtz LLM and Virtuvax B.V. today announce that the US Patent Office (USPTO) has issued patent RE. 47,471 dated July 2, 2019. The patent is a reissue of Mucosis’ US Patent No. 9,060,975 (“reset patent”). The granted patent contains twenty-five claims including thirteen original as well as modified claims of the reset patent plus twelve additi...
#ReSViNET , the Respiratory Syncytial Virus Network, selected the recent publication in AJRCCM on the SynGEM Phase I clinical trial as paper of the month March. The study which was executed by Imperial College London, showed that #SynGEM is safe and capable of inducing long term immune responses. A commentary published in the same journal suggested to test the vaccine in a human challenge study. The author manuscript can now be downloaded free of charge from the ReSViNET website
SynGEM a needle-free nasal spray vaccine against respiratory syncytial virus
SynGEM shown to be safe and immunogenic in healthy adults
SynGEM the first non-replicating intranasal RSV subunit vaccine to induce persistent antibody responses in humans
Groningen, the Netherlands, March 6, 2019 – Virtuvax B.V. and the trustee of biotech company Mucosis B.V., Mr. Holtz LLM today announce the results of a first-in-human study of the intranasal Respiratory Syncytial Virus (RSV) vaccine candidate, SynGEM. The study was executed by Imperial College London. Results of the study have been posted (in press) on the website of the American Journal of...
A new publication in the American Journal of Respiratory and Critical Care Medicine, headed by senior author prof. Louis Bont of UMC Utrecht makes a plea to consider further development of the SynGEM vaccine. Commenting on the results of the SynGEM RSV clinical trial, the authors indicate that the fail-fast approach that has been adopted by pharmaceutical industry, makes a challenging endeavor for development of RSV vaccines. Applying the fail-fast approach, the SynGEM vaccine was evaluated based on early results, generated until 56 days after start of the clinical trial. These early results were found inconclusive and consequently funding of Mu...
Today phase I clinical trial data of the Mucosis intranasal RSV F protein vaccine were published on-line. The vaccine was shown to be safe and immunogenic and was shown to induce long-lasting anti-RSV antibodies in healthy adults despite high pre-existing antibody levels. The study was designed as a phase I, randomised, double-blind, placebo-controlled trial in 48 healthy volunteers aged 18-49 year and was executed by Imperial College London. Results were published in the high rated journal AJRCCM.